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Scientific and technological breakthroughs do not necessarily lead to accessibility
of a new product to the public. There is no automatic and smooth transfer
from laboratory to product, and followed by delivery to the consumer. In order
to have useful innovation and product development, issues such as funding,
regulation, production and delivery need to be resolved not only by African
governments but also the international community, industry and civil society.
In this chapter we address following questions on the issue of transfer (or
translation): which technologies do health experts think have the greatest
potential to address Africa’s health challenges? what are the main barriers
and challenges to developing or accessing those technologies; and, what can
be learnt from the existing initiatives which are aimed at producing, supporting
or promoting the procurement and application of science and technology
(S&T)? It is important to note that the changes are complex and go beyond
the concept of simple transfer and thus need to be systematic.
To that end, we have proceeded as follows: summarised the recent work of
other groups on these questions; added the findings of our own Delphi survey;
examined in detail three types of key technological trends and opportunities
to see how they might be developed, and also to consider the constraints
to be overcome. A key premise of this chapter is that there are three basic
sets of challenges in developing technologies for diseases of the poor in
Africa. First, that scientific and technological challenges are key to addressing
specific diseases. Secondly, that it is essential to address market failures
and construct policies to improve the supply of and demand for appropriate
new health technologies and innovation. Thirdly, that greater attention be
paid to the ‘social technologies’ - the organisational and institutional mix -
involved in producing and distributing technologies.
CHAPTER 2
Abstract
Technological Trends and Opportunities to Combat
Diseases of the Poor in Africa
J. Chataway, K. Chaturvedi, R. Hanlin,
J. Mugwagwa, J. Smith & D.Wield
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Introduction
Scientific and technological advances have had numerous and profound impacts on public
health in both advanced and developing countries. One recent example is the development
of Highly Active Anti-Retroviral Therapy (HAART) which has transformed the chances of
those people living with HIV/AIDS (Badri et al. 2004). While these therapies do not cure
the disease, they certainly increase life expectancy and are seen as being partly responsible
for the reduction in the international AIDS death rate (The Economist 2008). Again, advances
in water purification also mean that it is now possible for more people to access safe
drinking water (Strestha et al. 2006), while innovations in genomics mean advancement
in the development of drugs, vaccines and diagnostics (WHO 2002). A 2002 report by the
Joint Centre for Bioethics at the University of Toronto outlined the top ten biotechnologies
for improving health in developing countries. At the top of the list were modified molecular
technologies for affordable and simple diagnosis of infectious diseases (Daar et al. 2002).
In order that these and other technological advances have a greater impact on the health
of the poor in Africa, a number of constraints need to be understood and overcome, and
they include technical, economic, institutional and political. The development of HAART
has not resulted in immediate access to this technology by those who needed it in many
African countries (Montaner 2006). Access to such HIV/AIDS treatment in Africa has required
resolution of funding, regulatory, production and delivery issues by not only African governments
but also the international community, industry and civil society. At organisational and
institutional level, frameworks for developing an HIV/AIDS vaccine are fast evolving with
new challenges emerging all the time. Thus early in 2008, scientific challenges resulted
in calls for, and movement towards a return to laboratory science and away from clinical
trials in the AIDS vaccine field (Independent 2008). Major new investment in health research,
including although not as significantly for neglected diseases1, affords exciting opportunities
and has built momentum (Hotez et al. 2008). What can be learnt from existing initiatives
aimed at producing, supporting or promoting the procurement and application of these
advances? And, how can African policy makers and the international community best move
forward such initiatives and provide access to these technologies? Addressing these questions
is the starting point to mapping the current status of current technological trends and
opportunities to combat the diseases that afflict the poor in Africa.
1. The Current State of Science and Technology for 
Health in Africa
There is an increasing realisation of the importance to build infrastructure in science,
technology and innovation for the development of nations in Africa. This is likely to translate
into progress towards the United Nations’ (UN) Millennium Development Goals (MDGs)
aimed at reducing poverty, disease and hunger in the world. NEPAD has a whole programme
devoted to Science and Technology, the Commission for Africa Report (2005) highlighted
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the importance of science, technology and innovation for Africa’s development and the UN
Millennium Project set up a Task Force to investigate the role of science and technology
for development. In order to overcome the competing policy demands and ensure an
emphasis is placed on science and technology (S&T), the UN Millennium Task Force on
Innovation (2005) emphasised a deliberate and systemic approach to the inclusion of, and
application of, S&T highlighting the learning process of innovative activity. Chapter 1 of
this volume articulates the arguments for Systems based approaches in more detail.
Some African countries have already adopted a systemic approach to S&T. South Africa,
Kenya and Egypt have all introduced S&T policy initiatives that work to build a ‘national
system of innovation’. By this system, policy decisions enable the creation of a network
of public and private institutions throughout all areas of the economy which work towards
the creation and diffusion of S&T. For example, since 1996 when South Africa launched
a White Paper on S&T, the country has placed an emphasis on networked multiple stakeholder
involvement, competitiveness and collaborative research in areas of heath research. This
means that there are focus areas for S&T innovation in biotechnology and nanotechnology
as well as collaborative research projects around HIV and malaria vaccines. As a result
it has been argued that South Africa is producing a ‘health innovation program’ within its
national innovation system (Mahoney and Morel 2006).
There has been a massive increase in international support for work on neglected diseases.
Bilateral and multi-lateral initiatives were spawned over the last decade and new global
health partnerships have attracted billions of US dollars in financial support in recent years.
Many of these initiatives are based to some degree on awareness of the importance of
all three fundamentals of building new technologies and innovations to address diseases
of the poor.
Despite this, Africa still has relatively low levels of research and development (R&D) and
health innovation. Almost no African country reaches the investment target of 1% of GDP
in R&D set in the Lagos Plan of Action (AU/NEPAD 2006). NEPAD and the African Union’s
Science and Technology Consolidated Plan of Action outlines other features of low levels
of investment:
“Africa’s low investment in science and technology is also manifested in declining
quality of science and engineering education at all levels of educational systems.
Student enrolment in science and engineering subjects at primary, secondary
and tertiary levels is also falling. The continent is also loosing some of its best
scientific and technical expertise to other regions of the world. In many countries
infrastructure for R&D has been neglected and is decaying. Institutions of higher
education, particularly universities and technical colleges, are in urgent need
of renewal after many years of neglect and disorientation from local and national
priorities.” (AU/NEPAD 2006)
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The quote highlights the poor situation of African nations’ S&T infrastructure. The lack of
emphasis and attention placed on S&T in investment, economic and education policy is
highlighted above. However, there has also been neglect of science and technology in
health policy too (the emphasis being placed on the output of the health system – healthcare
and its delivery) and vice versa (S&T policy did not include health components traditionally);
a situation being compounded by small and competing budgets. For example, the World
Health Organisation in its World Health Report (WHO 2001a) defines the health system
in terms of ‘healthcare’ while the Commission for Macroeconomics and Health (2001)
highlighted the lack of emphasis placed on health within science and technology policy.
The emphasis has traditionally been on seeing each of these areas as separate to each
other with only minimal inputs and linkages between them.
1.1 The Innovation Cycle – Building Sustainable S&T
A key lesson from the success of a number of countries in East and South East Asia is
not just the need for investment in S&T, and in education, but the key role of problem-
oriented innovation – the applied S&T that can solve problems and bottlenecks with new
products and processes. One important lesson from South East Asia is that a problem-
oriented focus – whether on new product development or on better or cheaper ways of
delivering services -- seems to result in improved innovation. Scientific and technological
capabilities are crucial and require resources. But these capabilities must be focused and
honed on key innovation goals – improved or cheaper treatments, for example.
As the concept of a systemic approach to S&T suggests, successful innovation of technology
requires more than the creation of a technology. It is important to acknowledge the complex
interplay of numerous contextual factors. Innovation does not occur within a linear framework
through which inputs of skills and resources at the discovery phase will automatically lead
to the production of a technology product, process or service. The innovation process is
in fact highly complex involving actors and linkages between industrial, education and
healthcare sectors.
In recognising the complex nature of innovation, it is therefore important to consider
technological innovation at all stages of the innovation cycle (discovery, development and
delivery; WHO 2006). This will ensure technologies move from bench to bedside. In order
for successful technological advance to occur it is important to consider the inputs, influences
and obstacles that occur when a technology is researched, produced and delivered. The
three stages and their linkage in health are best illustrated in Figure 1.
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Figure 1: The Innovation Cycle
Source: WHO (2006)
Discovery, development and delivery are all stages within a cycle of innovation; they do
not occur in a linear fashion but include multiple feedback loops between the stages while
once a technology has been delivered, end-user feedback provides inputs on which further
discoveries and adjustments to a technology can be made. In many developing countries
there exists a gap within the innovation cycle, however, due to the lack of market demand
for the development of products, processes and services appropriate to the disease burden
of a country. No one firm or other economic unit sees investment in research and technology
as in their interest or domain. That means that needs are not automatically met with
investment and product development. There is a lack of incentives to ensure the linkage
is made in the cycle between the delivery stage and further discovery activities. One way
to incentivise investment in these areas is through the use of public-private partnerships,
institutional arrangements that link the public and private sector to share the risks and
benefits of R&D activities. Where investment in science and technology does occur as a
result of public sector investment, that investment is often modelled on traditional notions
of scientific excellence which may result in good theoretical understanding, but not on
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deliverables (Chapter 1, this volume). These are just one set of a number of barriers that
exist in ensuring a continuous cycle of innovation occurs. Box 1 highlights the various
barriers that exist through the case study of diagnostics for tuberculosis in resource-poor
settings.
Two billion people or 30% of the world’s population are infected with Tuberculosis
(TB). The disease results in eight million new infections and 2 million deaths
every year. South Africa has the highest incidence of TB of any country in
the world. TB is an infectious disease which commonly affects the lungs.
Accurate diagnosis of TB is difficult in resource-poor settings. The microscopic
examination of sputum (mucus from the lungs) is still the only widely available
diagnostic tool for identifying TB in most developing countries. However,
under field conditions sputum smear microscopy shows a sensitivity of only
40-60%, partly due to the difficulty of maintaining well-equipped laboratories
to perform it and the need for specialised training but mainly due to the
inherent low sensitivity of the test. Poor sensitivity is exacerbated in the
presence of HIV co-infection (falling as low as 20%) because it becomes
difficult to see the bacilli within the sputum.
New diagnostic tools for TB detection have been developed and introduced
in developed countries. However, they have generally not been adopted in
resource-limited, high-burden countries due to cost, complexity, lack of
laboratory infrastructure or inadequate performance in endemic settings (e.g.
failure to adequately discriminate between diseased patients and latently
infected or vaccinated subjects). Novel technologies successfully introduced
into developed countries require adaptation to match the needs of developing
countries. The perception of companies involved in diagnostic tool development
that this will not lead to an adequate return on investment has hampered
subsequent introduction of such tools in high-burden regions.
Much of the basic research and discovery led activities into new diagnostics
for TB is therefore conducted within the academic setting or by small start
up companies who lack the funds to translate their discoveries into finalised
products. Lack of sufficient market data has exacerbated this situation in the
past in not providing sufficient incentive to larger pharmaceutical companies
who have the money to conduct costly product development and move a
new diagnostic tool to market. At the same time there is a perception that
distribution of new diagnostic tools will be difficult, expensive and the costs
hard to predict.
In order to move TB diagnostic tool development forward a number of
partnerships have been set up that bring together public funds and private
sector expertise (e.g. STOP TB Partnership and the Foundation for Innovative
Box 1: Tuberculosis Diagnostics in Resource-poor Settings
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New Diagnostics, FIND) to ensure new products are screened and that new
product developments are initiated and introduced into the market. These
initiatives ensure the provision of market data and advocacy and communications
activities, the support of product specification process and co-funding of
product development as well as facilitation of access including assisting and
building up local regulatory processes. As such, these initiatives provide a
means to complete the innovative cycle not only eliminating the gap at the
translational research and market approval and manufacture level but also
work to create demand for these products through their communication
activities.
Source: Adapted from Stop TB (2006)
Innovation also occurs at multiple levels: macro, sectoral and micro (Chataway et al. 2007)
and therefore it is important to develop policy relevant for innovation at all levels. Innovation
requires an enabling macro level environment created through effective regulatory frameworks
and national policies that strengthen the innovative environment. At the sectoral level a
health system needs the capacity to take up and absorb any new technological products,
processes or services that are produced and delivered through the micro level institutions
and organisations working in health innovation activities. At each of these levels there is
a dynamic and ever evolving interplay between actors from different sectors (health, education,
industry etc.).
Considering innovation’s procurement, development and application through such a systemic
lens that acknowledges the cyclical and multiple layered nature of the innovation process
will better enable sustainable and long-term successful implementation of chosen technologies.
The process of innovation is not only cyclical and layered but further complicated by the
interplay that occurs within it. Innovation usually occurs in a path dependent fashion (previous
patterns of investment, resource deployment, technological trajectories and accumulated
skills limit the scope for new technology to be discovered, developed and/or delivered).
More targeted health innovative activity requires a specific catalyst or dedicated manipulation
of policy and the wider environment.
The policy and infrastructural environment of a country’s ‘health innovation system’ – the
network of institutions, organisations, rules and norms that conduct innovative activities to
find solutions to the country’s health problems – described above will impact the ability of
the country to innovate – to choose, discover, develop and introduce (new) technological
advances. There is also no single tried and tested way of developing a health innovation
system to ensure technology innovation can occur. Every country has different capabilities
and capacities that each work in different ways and are influenced by different sets of
economic, social and political contexts affecting innovation. Thus, creating new approaches,
new technological platforms and introducing new innovations is far from straightforward.
Excellent analysis of the challenges involved has to some extent already informed efforts
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to create new technologies. Recent policy thinking about ‘market failures’ and incentives
from governments and other actors is sophisticated and challenging. Public private partnerships
(PPPs) such as the International AIDS vaccine Initiative (IAVI), Medicines for Malaria Venture
(MMV) and others are fully aware that developing science and technology in ivory towers
and expecting smooth and unproblematic translation to product development is extremely
unproductive. Yet, the challenges in creating new technologies that really address the
problems are huge. Those involved in analyzing these challenges and those trying to develop
and deliver new treatments are aware that the ‘social technology’ needed to address the
medical and health needs of the world’s poor is lacking. Radical improvements in the
understanding of how we create new paths through research, product development and
delivery are needed. New approaches to encouraging new forms of communication and
institutional/organisational mixes to bridge the various gulfs in thinking and action are
required.
2. Mapping Recent Advances
There have been attempts at identifying technologies that appear to provide significant
opportunity in combating diseases of the poor in Africa (cf. Daar et al. 2002; Grand Challenges
in Global Health 2005; Jamison et al. 2006a; UN Millennium Project 2006). In particular,
increased importance is being placed on biomedical and biotechnical advances in the life
sciences, biotechnology and other technological advances over more systemic and social
based technological advances to control diseases affecting developing countries. Of note
are two reports which highlight these differences: the 2002 ‘Top Ten Biotechnologies’ report
(Top 10 report; Daar et al. 2002) from a group at the University of Toronto and the more
recent Disease Control Priority Project’s second report (DCP2; Jamison et al. 2006a).
Daar et al. (2002) outline the results of an in-depth survey of 28 eminent scientists and
health policymakers to identify priority technologies to be used to improve the health of
populations in developing countries. The report listed the following 10 biotechnologies as
having the potential to improve health in developing countries: molecular diagnostic tools
such as PCR (polymerase chain reaction); recombinant vaccines; vaccine and drug delivery
systems; bioremediation (for environmental improvement); sequencing pathogen genomes
to identify new anti-microbials; female controlled protection against sexually transmitted
infection; bioinformatics; nutritionally enhanced genetically modified crops; recombinant
therapeutic proteins and; combinatorial chemistry for drug discovery.
Jamison et al. (2006a) outline – amongst other things – the science and technology with
the potential for future disease control in terms of biomedical research. The new technologies
that it lists are: genomics, proteomics and cell biology; stem cell and organ therapy;
information technology; diagnostics and hospital practices (surgery); human development
and child and maternal health; neuropsychiatry; nutrition and genetically modified crops;
social and behavioral science and; health systems and health economics.
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What is important to note at this point is that the Top 10 report is exclusively dealing with
technological advances relating to biotechnology2 acknowledging the potential of genomic
based solutions outlined in the ‘Genomics and World Health’ report (WHO 2002). It is
principally an exercise in foresight that places the emphasis on scientific progress. The
DCP2 report does place an emphasis on biotechnology based solutions but it does not
focus exclusively on them. The focus of this report is on disease control more generally
and how to reduce the incidence of disease within developing countries. In particular the
emphasis is placed on where to allocate scarce resources within the health system. As
such this report acknowledges that potentially useful technologies include process based
technologies and social systems focused on human development and strengthening health
systems.
Finding solutions to the chronic health problems that affect many African countries (as a
result of diseases such as HIV/AIDS, TB and malaria) involves improved capacities to
conduct scientific research to produce new drugs, vaccines and diagnostics. However, the
argument put out in the DCP2 report suggest that equally important process based technological
advances are required to ensure the technological products can be delivered appropriately
and effectively. The DCP2 report highlights the importance of focusing not only on the
development of purely scientific and technological product and processes as a means of
combating disease but also on the need to have good organisational and institutional mixes;
the importance of good ‘social technology’.
Decisions about a choice of technology can be made based on a wide range of factors.
Decisions about how a technology is sustainably developed and delivered can involve
complex trade offs such as between short term gain (immediate results e.g. reduced disease
burden) and longer term health returns (building sustainable health systems and processes).
Trade-offs are also required between specific health related S&T e.g. development of drugs
and vaccines for HIV/AIDS and other less ‘technical’ options that are also important e.g.
clean water and improved sanitation.
The trade-offs (and their implications for the degree of focus on biotechnology based
technological advances alone) require consideration if useful and relevant scientific and
technological opportunities are to be advanced that have the potential to combat diseases
of the poor in Africa. Thus in 2006 we conducted a mapping exercise that used these two
reports as a base and aimed also to consider the opportunities relating to social innovation
as well as science and technology. The mapping exercise consisted of an extensive literature
review and a Delphi-type survey of prominent scientists and health policy makers the details
of which are given below.
2.1 Survey Process
Using principally survey techniques – particularly an adapted Delphi technique – we aimed
to gain an insight into what the major experts in public and international health, science
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and medicine believe are the scientific and technological advances with the greatest potential
to address Africa’s major health challenges as well as the barriers to their advancement.
The survey data was added to material gained from a literature survey and analysis in
order to develop an overview – particularly working using case studies – of initiatives and
areas of attention that offer hope or need scrutiny by African policy makers and the
international community in order for the identified scientific and technological advances to
be maximised.
Over 100 key experts from around the world were emailed twice using a similar format
to a ‘Delphi’ survey. The experts included those particularly from Africa who are key medical
and biological scientists as well as those involved more generally in the field of public and
international health and specifically the diseases of poverty. We also contacted key actors
from global health initiatives and those working in interesting new initiatives such as drug
trial centres, multi-disciplinary clinical ventures, vaccine initiatives, etc. The response rate
was not as high as expected with a 15% response rate to the first email and a 10% response
rate to the second. A restricted time scale was the principal reasoning for the low response
rate. The respondents were not always the same people on both occasions. Respondents
came from a range of specialisms both from within the traditional and social sciences.
The first round of the survey consisted of an email requesting the respondent to rank in
order of importance what they saw as being the five recent advances in the life sciences
and related technological innovations that offer greatest potential to address Africa's major
health challenge. We also asked respondents to list the key barriers to advancing these
technologies in, and for, Africa in the next few years. A number of the responses were
followed up with telephone calls to discuss the responses in more depth.
The replies were analysed and a list produced outlining the most frequently and highest
ranked responses received by those that responded to our survey. These were then
tabularised (see Table 1) alongside the technological advances identified in both the Top
10 and DCP2 reports.
Table 1 was then sent out by email to all 100+ experts who were asked to review the table
and pick out five of the technologies listed that they saw as having the greatest potential
to address Africa’s health challenges, and to list their reasoning for the choices they had
made.
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Table 1: Recent Health Technologies with Potential to Address Africa's 
Health Challenges
Top 10 Biotechnology
Molecular diagnostic tools such as
PCR (polymerase chain reaction)
Recombinant vaccines
Vaccine and drug delivery systems
Bioremediation and environmental
improvement technologies
Sequencing pathogen genomes to
identify anti-microbals
Female controlled protection against
sexually transmitted infection
Bioinformatics
Enriched genetically modified crops
Recombinant technology for
therapeutic products (e.g. insulin)
Combinatorial chemistry for drug
discovery
DCP2
Genomics, proteomics and
cell biology
Stem cell and organ therapy
Information technology
Diagnostics and hospital
practices (surgery)
Human development and child
and maternal health
Neuropsychiatry
Nutrition and genetically
modified crops
Social and behavioral science
Health systems and health
economics
Our Survey
HIV/AIDS treatment in
the form of anti-retroviral
drugs
Insecticide treated bed-
nets for malaria
Artemisinin based
malaria drugs
Information technologies
Vaccines
Diagnostics
The results gained are outlined below. The exercise aimed to feed back those advances
most mentioned by experts first to obtain a sense of whether there is consensus. However,
and as importantly, the exercise also attempted to move beyond lists, by looking at reasoning
for choice, in order to gain more in-depth insight into the implementation and access issues
that require attention.
2.2 Survey Results
The survey is not intended to be representative or statistically significant but to get a snap-
shot view of current thinking and trends. The survey was also not intended to supersede
the work conducted by University of Toronto or the Disease Control Project. Instead the
survey was designed to complement these studies and see if attitudes and perspectives
had moved beyond biotechnology related advances in the way that the DCP2 report suggests.
Thus the results of our survey and the discussion that follows are presented here in
conjunction with the results of the Top 10 and DCP2 reports.
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Table 2 outlines the results of the survey. Two of the advances highlighted in our survey
are more disease specific than those mentioned in other reports: HIV/AIDS treatment and
malaria treatment/prevention. Rather than emphasising general life science based technological
advances the respondents in our survey highlighted the importance of combating HIV/AIDS
and malaria due to the high disease burden inflicted by these diseases on Africa’s populations
with one respondent saying the starting question that needed to be asked was, “what is
the evidence of the effect of having the technologies in place”.
As such respondents felt:
“I believe vaccines would be directly pertinent to the three leading infectious
disease burdens of HIV, TB and malaria (as well as a few other cause infections)
and an affordable, effective, and practical vaccine would directly avert a large
amount of morbidity and mortality.”
“HIV/AIDS treatment via ARVs – most immediately beneficially effect for those
infected with HIV.”
In particular the main disease specific technologies put forward included antiretroviral (ARV)
treatment for HIV/AIDS, vaccines for HIV/AIDS and malaria together with malaria drugs
based on artemisinin. In the first round of the survey we also received a large number of
inclusions of microbicides against HIV/AIDS and long-lasting insecticide treated bednets
for malaria. Other less frequently cited technologies which are also less traditionally ‘scientific’
in make up were cell phones, the internet, residual spraying for malaria control, clean water
and sanitation.
Other respondents chose to focus on generic life science based technological advances.
The decision to focus on generic technological solutions was highlighted by one respondent
who in the second round picked the category of ‘genomics, proteomics and cell biology’
as the main technological advance with most potential arguing “these cut across all subjects,
and carry potential for use by local scientists to address their own national problems.”
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Table 2: Health Technologies Ranked in Order of Potential to Address 
Africa's Health Challenges
Top 10 Biotechnology
Molecular diagnostic tools such as
PCR (polymerase chain reaction)
Recombinant vaccines
Vaccine and drug delivery systems
Bioremediation and environmental
improvement technologies
Sequencing pathogen genomes to
identify anti-microbials
Female controlled protection against
sexually transmitted infection
Bioinformatics
Enriched genetically modified crops
Recombinant technology for
therapeutic products (e.g. insulin)
Combinatorial chemistry for drug
discovery
DCP2
Genomics, proteomics and
cell biology
Stem cell and organ therapy
Information technology
Diagnostics and hospital
practices (surgery)
Human development and child
and maternal health
Neuropsychiatry
Nutrition and genetically
modified crops
Social and behavioral science
Health systems and health
economics
Our Survey
Vaccines (including
delivery systems
Diagnostic tools
HIV/AIDS treatment in
the form of anti-retroviral
drugs
Nutrition and genetically
modified crops
Health systems and
health economics
Sequencing pathogen
genomes to identify anti-
microbials
Malaria treatment (with
Artemisinin) &
prevention (with bed-
nets)
Four main generic life science advances were mentioned most frequently in our survey.
Recombinant vaccines and their delivery systems were seen to be important because they
“[w]on’t be the answer to everything, but there are still huge gaps in infectious disease
control, resulting in great disease burdens” and are “[l]ikely to provide protection for a
variety of diseases in a safe manner.” It was felt that “[t]here will be no effective treatment
at individual and community level if we do not have the respective diagnostic tools and
strategies at the point of care (i.e. not in any specialised centre, possibly even in the North).”
GM crops and “better nutrition and crop yields would not only yield better food security
and reduce hunger (another MDG) but also help improve performance at school and generate
at the family/village level excess marketable produce which can start to create wealth to
reduce poverty.” The fourth generic advance that was identified was sequencing of pathogen
genomes to identify microbials.
In fact the reasoning for a technology’s inclusion by respondents differed slightly in each
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of the two Delphi rounds. Predominately in the first round of the Delphi many of the
respondents to our survey highlighted how burden of disease was one of the main factors
influencing their ranking decisions. Ranking decisions in the first round were also based
on the degree to which technologies were also readily available for introduction. In the
second round, the reasoning given was much more placed on optimism and the need to
improve difficult current situations as quickly and as efficiently as possible.
Such reasoning echoes that found by the researchers of the Top 10 report who reported
the following factors as being important in assisting biotechnological advance:
• Impact
• Appropriateness
• Burden
• Feasibility
• Knowledge gap
• Indirect benefits
The need to consider multiple reasoning in choosing technology is illustrated by this quote
taken from an interview of one respondent:
“ARV trials are getting quite exciting and showing promising results. Certainly
potential is there but treatment and care needed includes HIV/AIDS prevention,
counselling and testing, nutritional management, and, of course, access to ARV
drugs. Money needs to be invested in education, training and healthcare
resources as well as in developing new drugs. Besides, national and local
policy leadership is a big issue.”
The difficult choices required in deciding which technologies to focus on were also highlighted
by another respondent:
“I'm having real trouble with the lists. I think it's very tough to compare, for
example, "health systems and health economics" with, for example, "recombinant
technology for therapeutic products" and tougher still to compare "human
development and child and maternal health" with "sequencing pathogen genomes
to identify anti-microbials". Of course, none of the rest of it makes much
difference unless you have a health system (of some kind -- maybe more private
sector than public but still a system) or a commitment to human development
so I suppose those things have to go to the top of any list.”
An emphasis throughout the survey – and as illustrated by the above quote – was also
placed by respondents on the need for integrated approaches – the need to focus on more
than one of these technological advances at any one time:
“It is the combination of ACT [Artemisinin-based Combination therapy] with the
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use of bednets that will make a huge difference. I deliberately put them together
as only the integrated approach of combining the curative and the preventive
approaches will lead to success”
“I believe the shortage in many countries of capable health workforce and weak
health systems, if they were addressed successfully, would enable the delivery
of a range of cost-effective interventions such as bednets. The effective use
of health systems/ health economics would lead to the use of other valuable
technologies. Without the systems and economic tools, the justification for
prioritizing these technologies may not be so clear and the resources to deliver
them may not be developed.”
The inclusion of health systems and health economics was therefore identified as both a
barrier and an advance in dual measure. Weak health systems and poor economic tools
were seen as hindering the ability to introduce and use other potential technological advances.
Stronger and more effective health systems were seen to provide an enabling environment
necessary to ensure that technologies were developed and their opportunities realised.
Functioning health systems were seen as an overarching requirement for all the other
activities and technological advances to take place. An emphasis was not so much placed
in this respect on science and technology but more on the need for innovation in the area
of health systems and their analysis. More specifically these answers relate to the importance
of ‘social technologies’ or the importance of the right organisational and institutional mix
throughout the research-development-access continuum.
Thus our mapping exercise has highlighted three types of technological advance with the
potential to combat diseases of the poor in Africa. We have identified a number of generic
life science and biotechnology based advances in the form of vaccines, diagnostics, genome
sequencing and GM crops. Secondly we have identified a number of disease specific
interventions for malaria and HIV/AIDS. And thirdly, we have identified the importance of
‘social technologies’ or the organisational and institutional mix that is necessary to ensure
successful development and/or uptake of the generic scientific and disease specific
technological advances.
This final set of technological advances relates particularly to the reference by respondents
to the importance of health systems and health economics. This reference is a worrying
reminder that problem-oriented R&D has to include analysis of the problem of how to deliver
new health innovations. Just as products must now be designed for use as well as for
cheap manufacture and recycling, health technologies must be designed in function of their
use in difference types of location.
As such, this initial assessment of new technologies highlights the need to think hard about
policies and practices that pull together new science and technology, like ‘sequencing of
pathogen genomes’ with choice factors such as ‘the burden of disease’. This requires radical
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new ideas that link science, technology and innovation communities with health practitioner
communities, locally, nationally, regionally, and internationally.
3. Mapping Technologies and their Application
As highlighted above, in reviewing our survey results and the Top 10 and DCP2 reports,
we can identify six life science based technological advances and one ‘social technology’
advance (health systems and health economics) that have the potential to address Africa’s
health challenges from diseases such as HIV/AIDS, tuberculosis, malaria, cholera etc.
These can be grouped into the following categories:
1. Generic life science based technological advances:
• recombinant vaccines;
• diagnostic tools;
• sequencing of pathogen genomes to identify anti-microbials; and
• genetically modified crops.
2. Disease specific technological advances for HIV/AIDS and malaria:
• Vaccines for HIV/AIDS and malaria;
• Malaria drugs;
• HIV/AIDS drugs; and
• Microbicides.
3. ‘Social’ technology innovations particularly in the form of functioning health systems 
and their analysis. These relate to the need for the correct combination of funding, 
infrastructure and skilled personnel who are linked into supporting networks.
Each of these will now be introduced before more in-depth analysis in Section 3.4 of their
potential and impact, status and constraints impacting their advance. The discussion of
these technologies in this section uses the work of the Toronto group’s Top 10 report as
a base and updates this information where appropriate. The decision to include in this
discussion the concept of a ‘social technology’3 is due to the importance of advances in
the (social) interactions between and within innovation communities and those working
within the health system as much as the importance of having a new drug, vaccine or
diagnostic available.
3.1 Generic Life Science Based Technological Advances
The Top 10 report highlights the importance of biotechnology based technological advances
and the potential of a number of these to combat diseases of the poor in developing countries
(see Table 3). Our mapping exercise highlighted three of those listed in this table which
are deemed to provide an opportunity to address the main health related MDGs of combating
poverty, reducing child mortality and improving maternal health. These, together with GM
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crops which the Top 10 report also highlighted and which is seen as necessary to contribute
to the MDG on improving children’s nutrition, will now be discussed. We will consider the
current status and (the extent to which they are available and being used in Africa).
Table 3: Priority Biotechnologies Identified in the Top 10 Report
Technology
Recombinant
Vaccines
Improved
vaccine and drug
delivery methods
Sequencing of
the genomes of
pathogens and
their vectors
Molecular
diagnostics
Recombinant
proteins
Combinatorial
Chemistry
Advantages
Reduced risk compared with
attenuated vaccines & rational
vaccine design
Needle-free technologies reduce
need for trained personnel, risk
of HIV infection controlled,
release systems help overcome
non-compliance heat-stability &
eliminates need for refrigeration
Boosts search for novel drugs
and vaccines & improves
understanding of disease
mechanism
Early detection, timely
intervention, helps prevent
spread of infection & avoids
waste of resources on
inappropriate treatments
Synthesis by transgenic plants
and animals & potentially
cheaper than mammalian cell
culture
Rapid generation of many
varieties of chemical compounds;
Increased efficiency, potentially
lower costs, fewer by products
Examples
Malaria subunit vaccine RTS,S (with AS02
adjuvant) in phase 3 clinical trials in children
in Mozambique
Temperature-stable, controlled-release
formulations of synthetic peptide analog
of hepatitis B antigen and trehalose ester
derivatives
Ten strains of West Nile disease vector
Culex pipiens, one strain of malaria-carrying
Anopheles gambiae have same point
mutation in acetylcholinesterase for
insecticide resistance
Dipstick assay for the detection of
Salmonella typhi-specific IgM antibodies,
same-day results, small volume of serum
needed, stability of reagents and simplicity
of assay allow use in absence of laboratory
facilities
Cheaper biosynthesis of antimalarial
artemisinin by Escherichia coli engineered
to express yeast mevalonate isopreniod
pathway proteins
Two new classes of drugs inhibit Leishmania
mexicana cysteine protease, found from
combinatorial library of 150,000 compounds
Source: Lambo (2005) and based on Top 10 report findings
3.1.1 Recombinant Vaccines
Biotechnology has helped in the development of recombinant vaccines with many advantages
over conventional technology, and has been applied to develop new and improved diagnostic
assays which are cheap, rapid, sensitive and strain specific. The classic types of vaccines
are all limited in their dependence on biological products, which often must be kept cold,
may have a limited life, and can be difficult and expensive to produce. The development
of recombinant vaccines – those using chromosomal parts (or DNA) from a different organism
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inserted into a foreign cell4 - has generated hope for a new generation of man-made
vaccines.
Vaccines stimulate an immune response in the body and can therefore reduce the chances
a person has of an infection contracting a serious level of infection. Vaccines are the
ultimate prevention tool being responsible for the total eradication of smallpox and the
virtual eradication of polio in the world. However, vaccine science is complex and not every
infection and disease has a vaccine against it. This is particularly true of the big killers,
HIV and malaria while the tuberculosis (BCG) vaccine was developed nearly 100 years
ago and its effectiveness is questioned (Novelli 2006).
Traditionally vaccines were either killed or weakened (attenuated) forms of whole pathogens.
With modern recombinant technology it is possible to be much more precise in controlling
vaccine characteristics. It is therefore possible to work with only specific parts of an infectious
organism (in the case of subunit vaccines) through the antigens. One such vaccine is the
hepatitis B vaccine. One of the first recombinant vaccines to be approved for human use
is made using recombinant yeast cells genetically engineered to include the gene coding
for the hepatitis B antigen. Because the vaccine contains the antigen, it is capable of
stimulating antibody production against hepatitis B without the risk that live hepatitis B
vaccine carries by introducing the virus into the blood stream.
Other molecular biology tools have made it possible to identify which proteins are conserved
among different strains of a virus or bacteria, or which are responsible for virulence of
pathogens or oncogenesis in tumours. These proteins may be good candidates for vaccines.
There are also novel approaches being taken to produce what are known as naked DNA
vaccines which use a plasmid (a circular piece of DNA that self-replicates) as a vehicle
to carry a pathogen into the body against which the body produces antigens to stimulate
immunity. These are novel because they would not require a cold chain mechanism which
currently hampers much immunisation effort in Africa. Plant vaccines also offer hope. The
most promising option here is not necessarily vaccines being developed in plants which
are then eaten but where antigens are expressed from plants such as tomatoes or potatoes
and then processed into a dose regulated form such as a capsule which again requires
no cold chain and can easily be taken involving no needle pain. As medical knowledge
has increased researchers worldwide are working towards developing new vaccines and
therapeutics for cancer, tuberculosis, melanoma, AIDS, influenza, and malaria based on
r-DNA.
3.1.2 Diagnostic Tools
The use of accurate diagnostic tools to detect pathogens through associated molecules
such as DNA and proteins in cells and blood is vital in controlling disease. As such the
group of experts surveyed in the Top 10 report voted accurate diagnostic tools as “the
most prominent biotechnology for improving health in developing countries in the next 5-
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10 years.” In particular the report mentioned advances in PCR, monoclonal antibody and
recombinant antigen technologies as having the potential to revolutionise the diagnostic
tools that are available for disease control in developing countries.
Several enzymatic amplification processes, generally categorised as nucleic acid amplification
techniques, have been developed and introduced as commercial products in developed
countries. The most widely used are PCR, TMA (transcription modified amplifications) and
SDA (strand displacement amplification). PCR allows for the production of multiple copies
of a specific DNA sequence quickly, safely and accurately. This technique can be conducted
within hours rather than days and can be used to identify more dangerous pathogens to
work with very safely (e.g. HIV). The technique can also identify pathogens that are difficult
to produce in laboratory conditions in the case of malaria and tuberculosis. The rapid and
accurate diagnosis of tuberculosis remains a major challenge for all developing countries
and particularly for Africa with TB in HIV positive individuals, in children and in patients
with extrapulmonary form of TB. PCR is increasingly being used to test for drug resistance
at the same time as identifying the disease pathogen. However, the level of sophistication,
complexity (requiring trained laboratory personnel) and cost associated with the technique
restricts its general application in resource-poor settings.
Anti-body coated dipstick tests (see Box 2) that diagnose disease are increasingly used
both within the clinical healthcare setting particularly in developing countries where electricity
and water are in difficult supply (they are single-use test kits) and where more advanced
medical centres are located at long distances from a community. Developments in the
areas of monoclonal antibodies (a number of identical mass produced cells from a single
parent cell) and recombinant antigens (mass produced antigens that are created by genetically
engineered organisms e.g. bacteria or yeast) are also used as the base for dipstick tests
(such as PATH’s HIV1 dipstick test) as well as ELISA (enzyme-linked immunosorbant assay)
screening where basic laboratory equipment is available to detect antigens and antibodies.
Although PCR and the other technologies have provided opportunities for the creation of
simple to use, rapid test kits, the cost of these kits and PCR can be expensive. The cost
of PCR testing is being reduced through the development of methods to test for more than
one disease at a time (multiplexing) and by modifying the storage and processing techniques
it requires, however the cost of these technologies may make these diagnostic tools beyond
the reach of many governments with limited budgets and competing demands on funds.
There has been successful transfer of PCR technology to developing countries through
the work of the Sustainable Science Institute in San Francisco and the Swiss Tropical
Institute in Tanzania with the local modification of equipment and the recycling of reagents
(Harris and Tanner 2000).
The DCP2 report highlights how other non-biotechnology related advances are also occurring
in the diagnostic tools area which include advances in imaging techniques such as magnetic
resonance imagine (MRI) scans, computer tomography and ultrasound. These have the
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opportunity to revolutionise healthcare in the developing world although the cost of these
technologies make them out of reach for many healthcare providers in the developing world.
The development of a pioneering new diagnostic tool for trachoma could help
to eradicate the most common cause of blindness due to infection.
Dr. Helen Lee and Claude-Edouard Michel of the Diagnostic Development
Unit at the University of Cambridge, and collaborators, have developed and
trialled a rapid dipstick test that can diagnose the presence of infection within
half an hour. The new 'point-of-care (POC) test' was developed specifically
for use in developing countries, as it is cheap, quick and simple to perform,
and requires no expensive equipment or skilled labour.
Dr Lee and team then compared the accuracy of this new dipstick test with
the gold standard polymerase chain reaction (PCR) test in a trial in remote
trachoma-endemic villages in Tanzania. The trial [in 2004 and 2005], involving
664 children aged 1-9, showed that the dipstick test was more accurate in
identifying the presence of infection, correctly predicting over 97 per cent of
cases, against 43.6 per cent for the current method.
The findings could profoundly influence the future diagnosis and treatment
strategies for trachoma worldwide.
Box 2: New Dipstick Test
Source: www.wellcome.ac.uk
3.1.3 Sequencing of Pathogen Genomes
PCR technology enables the efficient sequencing of pathogen genomes. The opportunities
afforded by this form of genome sequencing and that of parasite genome sequencing
provides the base for much modern health research. As such the Top 10 report highlighted
it as a ‘priority area’ while WHO devoted a whole report to the potential impact of genomic
research on world health in 2001 (WHO 2002). Genes regulate the organisms within the
biochemistry pathway and it is from this base that most diseases can be defined. As such
the sequencing of genomes provides a means of understanding how a disease is caused
or the makeup of a parasite and how it may be controlled. Sequencing – via a process
called the Sanger or Dideoxy method – is the discovery and recording of the nucleotide
sequence within an organism’s DNA. Knowing the sequence of a genome is the first step
to understanding its biology and finding ways of controlling it.
Genome sequencing is not only used in diagnostic tools such as PCR. Genome sequencing
is also providing an input into the production of vaccines and drugs by providing information
as to the gene sequence characteristics of important proteins. It is also possible to compare
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genomes of disease carrying strains and non-disease carrying strains of organisms to find
the differences that can be used as a way forward in drug and vaccine production.
Genome sequencing provides the opportunity to map the genetic layout of disease pathogens,
parasites, humans and animals (see Box 3). This provides a means of determining genetic
variability around the world between different species, countries and population groups.
Sharing genetic information between researchers through free websites such as HapMap
(www.hapmap.org) provides a means for all scientists throughout the world to be able to
access this information. Similarly, creating gene banks where large pools of generic data
are created is another source of data sharing which can be used as a base for research.
This is particularly important in the emerging field of bioinformatics whereby data is assembled
using computer based models and tools to search genetic data for clues about genetic
makeup and how to control and identify disease.
Unfortunately there are numerous scientific obstacles and a lack of understanding still
around how genes are expressed (Bentley 2004). Along side this are institutional roadblocks
that limit the access and knowledge around genomic sequencing. Currently the big genome
projects are based in the UK and the USA and the lack of genomic based research in the
developing world has created the phrase ‘the genomic divide’. The global genome mapping
project, HapMap, includes developing countries such as Nigeria while South Africa has
invested in setting up a bioinformatics institute and encourages private health biotechnology
firms to set up around innovation centres. On the whole however, the amount of basic
research, such as around genome sequencing, within biotechnology that is conducted in
Africa is small.
Box 3: Pathogen Genomes
"The parasite genome is very plastic," explained Dr Manolis Dermitzakis, co-
leader of the project from the Wellcome Trust Sanger Institute, "and carries
the scars of its battle against its three main challenges - our rapidly evolving
human immune system, the defensive responses of the mosquito and the
insecticides and drugs we use to challenge it."
"Our variation studies bring biology to the parasite genome, uncovering the
secrets of Plasmodium without - but as a prelude to - work in the lab. Our
overview of evolution points to those gene variants that are responsible for
disease effects - some were expected, but some are surprises."
Humans infected with malaria often carry several variant strains. A consequence
is that vaccines to combat malaria are very difficult to develop and may
become ineffective if the parasite switches its coat. Moreover, the range of
parasite diversity means that resistance to new drugs can become rapidly
established from small numbers of existing resistant organisms. Widespread
resistance to chloroquine has developed in only 50 years.
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The Plasmodium map of variation can be used alongside maps of human
variation, such as the HapMap or that of copy number variation published
in Nature recently by a team from the Sanger Institute, to understand how
the genome of each has been moulded by the activities of the other.
"The human genome carries imprints of our history of infection by malaria",
commented Dr Mark Walport, Director of the Wellcome Trust. "Similarly the
genome of the malaria parasite shows how it interacts with the human immune
system. Understanding these interactions is key to the development of effective
vaccines against malaria."
The new map was developed with biological expertise from researchers at
St George's, University of London and the Weatherall Institute of Molecular
Medicine, University of Oxford, John Radcliffe Hospital, Oxford. It is a snapshot
of Plasmodium evolution, and provides a wealth of information for the malaria
community, for example, by identifying genes that evolve too rapidly to be
good drug targets. It shows researchers where to search for new treatments
and where to avoid.
Source: www.sanger.ac.uk
3.1.4 Genetically Modified Crops
Improved nutrition can significantly improve the life chances of infants in the developing
world where malnutrition affects one in five people. One way of doing this is to genetically
modify staple foods such as cassava, maize, potatoes and rice. Traditionally to improve
a species of plant, farmers have cross breed two species to mix the genes and introduce
new genes into a plant. Genetic modification is a modern, biotechnological equivalent by
which a plant’s composition is modified by artificial means. This enables genes from one
species to be inserted into an unrelated species. Gene technologies can produce new
varieties more quickly than conventional breeding (Nuffield Council on Bioethics 2003). The
usual method is to insert a gene into an organism so that as that organism grows the genes
are taken up by the cell in which its placed. One example of this is Golden Rice, a variety
of rice that was modified to contain added vitamin A and iron.
Up to now, most GM crops have been grown with just two characteristics – herbicide
tolerance and insect resistance. Herbicide tolerance allows, in principle, farmers to kill weeds
but not crops, sometimes using less herbicide over the whole growing cycle. Similarly,
insect resistance allows, in principle, farmers to kill insects without damaging crops, sometimes
allowing fewer applications in total, lowering labour and insecticide. However, other
characteristics are possible with genetic modification, such as drought resistance, ripening
control, fat content, and nutrition.
There are arguments against the use of GM crops. These focus on issues of risk to humans,
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animals and the overall ecosystem balance in the production and consumption of GM crops.
At times these become part of a wider discussion around the way new technologies should
be regulated (Tait and Chataway 2007). This has led to resistance on the part of many
people to the introduction of GM crops including the refusal of some countries to receive
food aid from GM sources (Scott 2004). Proponents of GM crops however argue that they
could have significant potential on farming production and food production similar to the
impact of the ‘green revolution’.
One example is that of Vitamin A enhanced (Golden) rice has been produced with the
primary aim to help prevent vitamin A deficiency (VAD), which affects 14 million children
under five and is a prime cause of blindness. About 250 million children had sub-clinical
deficiency, one-third of whom live in rice eating areas of Asia. There are arguments about
whether golden rice is just a technofix, but public-private partnerships between companies
and researchers are ongoing, linked to building regulatory systems so that clinical trials
can ascertain whether the vitamin A in the rice will be taken in by the body. Research is
also taking place on vitamin A sorghum, including via a large consortium, the African
Biofortified Sorghum Project, funded by the Grand Challenges in Global Health Initiative
of African, American and Japanese institutions to enhance sorghum with iron, zinc and
vitamin C (AU/NEPAD 2006). Others are working on nutritionally enhanced cassava and
protein enriched potato.
3.2 Disease Specific Technological Advances for HIV/AIDS and Malaria
During our mapping exercise HIV/AIDS and malaria were two diseases that featured
prominently as those contributing to the significant burden of disease affecting many countries
in Africa. WHO (2005) estimates that 3.2 billion people a year are affected by a bout of
malaria and 1.2 million are killed. The highest mortality is amongst children and those living
in Africa where 90% of all malaria related deaths occur. About 39.5 million people are
infected with HIV/AIDS in the world. Of the 4.3 million new infections estimated to have
occurred in 2006, 65% were in Africa. The region now has 24.7 million HIV/AIDS infected
people (WHO/UNAIDS 2006).
Research into finding treatments and preventive technologies for these two diseases has
traditionally been hampered by low levels of funding and investment, particularly by the
private sector in the industrialised world – where much of the expertise and funding lies.
The increase in funding sources through philanthropic organisations e.g. the Bill and Melinda
Gates Foundation, and the development of new financing mechanisms e.g. International
Financing Facility for Immunisation are providing ways forward. There are also increasing
calls for African governments to take increasing responsibility and build their capacity to
do so (Dickson 2008; Hanlin, 2008).
Very significant amounts of money are being spent on HIV/AIDS research. In the period
2002 -2006, the EU spent 74.3 million Euros, however the US is by far the biggest country
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donor contributing 86% of all public funds raised for HIV vaccine research and 74% of all
microbicide investment. Overall, the US National Institute of Health spends approx US$2
billion annually on HIV/AIDS research although of course not all of this will be relevant
to developing countries. The science of antimalarial drug research has moved rapidly in
the past decade through a large networked approach with funding increasing considerably.
The European Union committed approximately 43.1 million over the period 2002-2006 (IAVI
2006). Total expenditure on malaria R&D in 2004 was estimated at US$323 million
predominately due to contributions from the US National Institute on Allergic and Infectious
Diseases and the Bill and Melinda Gates Foundation. The combined investment of these
two groups constituted 49% of malaria R&D investment. Three quarters of this money was
given to entities conducting research and research managers (particularly the partnership
groups of Medicines for Malaria Venture [MMV], Program for Appropriate Technologies in
Health (PATH’s) Malaria Vaccine Initiative and WHO’s Tropical Disease Research group).
Funding shortfalls for both HIV/AIDS and malaria R&D exist and few African countries
contribute significant national funds to promote such R&D investment with the exception
of South Africa which has heavily funded HIV vaccine development activities and to a lesser
extent microbicide research (de Francisco and Matlin 2006). Even once these products
are developed there is still however a major constraint to be overcome that is more than
simply financial. All drug, vaccines and diagnostics require strong access pathways and
this requires good distribution networks and demand for affordable, effective, easy to use
products. These access issues also need to be considered during discussions around
developing specific disease related technological innovations.
Technologically and scientifically there have also been barriers to advancing treatment and
prevention options. These will be discussed in more depth in Section 3.4 however it is
important to note here that, although great strides have been made in the areas of drug
treatments for HIV/AIDS and malaria, hope is provided by advances in other directions as
well. These come in the form of anti-AIDS drugs being used as a preventative (pre-exposure)
prophylaxis, improved condoms (both male and female), cervical barriers (such as microbicides)
and male circumcision (Padian et al. 2008; The Economist 2008). Advancement in vaccine
science for both malaria and HIV/AIDS has been much slower. It is expected that a malaria
vaccine will be produced in the coming years with a number of malaria vaccine candidates
having undergone and in the process of Phase III testing. An HIV vaccine is however still
much further off. The lack of success in preventative biomedical advances such as vaccines
and microbicides has led to a call for ‘combination prevention’ whereby known preventative
methods (such as condoms and circumcision) are combined with treatment of HIV/AIDS
(Cohen 2008). Again however, the emphasis here is on treatment and prevention of two
of the ‘big three’ (HIV/AIDS, malaria and TB) at the expense of other neglected diseases.
3.2.1 Malaria Drugs
The malaria burden on Africa demonstrated above is made worse by high levels of drug
resistance hampering treatment efforts. In recent years many countries in Africa have had
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to change their first line malaria drugs due to growing resistance particularly of Plasmodium
falciparum malaria to traditionally used treatments using chloroquine and even more recent
Sulfadoxine/Pyrimethamine treatment introduced in the wake of chloroquine resistance.
The WHO now recommends the use of artemisinin based treatments. Artemisinin drugs
first introduced in South-East Asia a little over a decade ago have proven to be well tolerated
and the most potent of antimalarials. However, artemisinin drugs have a very short half-
life and thus a multiple dose regimen of seven days is required to achieve an acceptable
cure rate. When artemisinins are used as monotherapy, recrudescence of malaria is common.
Combining an artemisinin drug with a partner drug that has a longer half-life improves the
efficacy of the artemisinin. It also reduces treatment duration with the artemisinin and the
likelihood of development of resistance to the partner drug.
The R&D required to produce these new combination therapies and the uncertain return
on investment has reduced the degree international pharmaceutical companies are willing
to invest in producing malaria drugs. To incentivise investment new innovative partnerships
are being used. One example is the work of MMV, a not-for-profit organisation which aims
to “bring public, private and philanthropic sector partners together to fund and manage the
discovery, development and registration of new medicines for the treatment and prevention
of malaria in disease-endemic countries.” (www.mmv.org). MMV currently has over 20
projects in its portfolio, representing what is widely viewed as the largest antimalarial drug
research portfolio ever. Following a fifth call for proposals which closed in February 2006,
MMV’s Expert Scientific Advisory Committee recommended seven new projects be added
to the portfolio, subject to contract and availability of funding. These projects include one
development project, four discovery projects and two natural products projects. MMV has
included two fixed combinations of artesunate, a semi-synthetic derivative of artemisinin,
with other known antimalarials to create chlorproguanil-dapsone-artesunate and pyronaridine
artesunate in its portfolio which show promise as new affordable ACT drugs for malaria
treatment (see Box 4).
Chlorproguanil-dapsone-artesunate (CDA) in sub-Saharan Africa
GlaxoSmithKline (GSK), the World Health Organisation’s Special Programme
for Research and Training in Tropical Diseases (WHO-TDR) and MMV are
collaborating in the development of the drug – a new-fixed dose artemisinin
combination therapy, combining chlorproguanil, dapsone and artesunate,
known as Chlorproguanil-dapsone-artesunate (CDA). CDA, which could be
a major weapon against malaria, is a fixed-ratio three-drug combination of
Lapdap™ with an artemisinin derivative, being developed to treat uncomplicated
Plasmodium falciparum malaria. A Phase II dose-ranging study in adults and
children with acute uncomplicated malaria has been completed using sites
in the Gambia and in Malawi, and the choice of artesunate dose for the fixed
Box 4: Malaria Drugs
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combination is now finalised. A Phase III clinical development programme
prepared according to International Conference on Harmonisation (ICH)
guidelines and the UK Medicines and Healthcare products Regulatory Agency
(MHRA) is underway in several African countries. In addition, a longitudinal
‘Phase IIIb’ trial is being designed at present, and discussions around the
design of a possible Phase IV programme are underway.
University scientists have already collaborated with GSK and other partners
to develop the anti-malarial, Lapdap™. This drug has a short half-life, which
creates a short ‘resistance selection window’ or exposure period, to the
parasite, helping to preserve its anti-malarial efficacy. CDA has been created
by adding artesunate to Lapdap to create a fixed-dose therapy and should
bring greater therapeutic benefits including more rapid parasite clearance
from the blood and reduced risk of drug resistance.
Pyronaridine and Artesunate (PANDA) Fixed Dose Combination
Pyronaridine-Artesunate is a new fixed-dosed combination based on artemisinin
combination therapy, currently the most effective type of antimalarial treatment.
The novel formulation technology applied to both drugs by Shin Poong of
Seoul, Republic of Korea, MMV’s partner in this development programme,
has resulted in Good Manufacturing Practice quality tablets. Single, repeated
doses escalation, interaction and food effect components demonstrated that
the combination was well tolerated, with pharmacokinetics showing improved
bioavailability and supporting once-daily dosing. PANDA has completed its
large Phase II studies with 470 patients in Asia and Africa. While data are
being processed for final analysis and reporting, planning has started for a
multi-centre large Phase III trial in Africa and in South-East Asia in both
children and adult patients. These studies will be followed by another study
in younger children which will assess efficacy of a new paediatric formulation.
If the Phase III trials confirm the phase II results, regulatory filing to the
European Medicines Agency (EMEA) and the Korean Food and Drug Agency
was expected by the end of 2007 with the new antimalarial ready to market
in 2008.
3.2.2 HIV/AIDS Drugs
HIV antiretroviral drugs or ARVs disrupt the action of the virus. There are various combinations
of these drugs which act at various different stages of the lifecycle of HIV (see Box 5).
The virus mutates very quickly and as such it is often necessary to change the drug regimen
being used to ensure it is most effective and resistance does not occur. Usually a cocktail
of drugs is used such as HAART which involves treatment with at least three active
antiretroviral medications. Treatment is highly effective but only if continued for life as it
is not a cure.
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Unfortunately there are a number of factors that hamper ARV access in Africa related both
to distribution but also production. Médecins Sans Frontières (MSF) (2006) lists the following
factors as hampering delivery of ARVs in developing countries:
• Shortage of health workers and the high costs charged to patients for the 
drugs and clinic visit;
• Too few children receiving ARVs because of the lack of diagnosis and treatment
tools as well as the lack of availability of strategies to prevent mother-to-child
transmission;
• Failure to coordinate TB and HIV control programmes and a lack of tools to
diagnose and treat TB in HIV patients and;
• Newer formulations and combinations of drugs are often not available or 
registered in developing countries resulting in a lack of access to the best
drugs that are available.
A related issue to the availability and cost of drugs relates to the form ARV drugs take
i.e. whether they are patented and so registered to the company that made them who have
sole rights to produce and market them (such as those listed in Box 5) and generic (non-
patented) variations which are significantly less in cost. Generic drugs have reduced the
cost of first line drug regimens (as opposed to second line regimens which are given
commonly when first line drugs do not work as a result of resistance or TB) by 99% to
an average cost of US$132 a year per patient. 50% of those taking generic drugs are
taking drugs produced in India. Since 2005 India has started enforcing Trade Related
Intellectual Property Rights (TRIPS) legislation which subject new drugs to up to 20 years
patent protection. Groups such as MSF argue that this has the potential to drastically effect
drug supplies to HIV patients around the world, including in Africa, through increased prices
(www.msf.org). Efforts such as WHO and UNAIDS’ ‘3x5’ initiative and William J Clinton
Foundation’s collaboration with drug manufacturers are however improving drug access
in Africa.
Each type, or "class", of ARV drug attacks HIV in a different way. There are
four main types of drug currently available:
1. The first class of anti-HIV drug was the nucleoside reverse
transcriptase inhibitors, also called "nukes". These drugs work by
stopping the HIV genetic material being converted from RNA into
DNA. Examples of such drugs are AZT (ZDV, zidovudine, Retrovir®)
and Tenofovir (Viread®).
2. Another class of drug blocks the same step of the life cycle, but
in a different way. This class is the non-nucleoside reverse
transcriptase inhibitors, or NNRTIs. Three NNRTIs have been
approved: Nevirapine (NVP, Viramune®), Delavirdine (DLV,
Rescriptor®) and Efavirenz (EFV, Sustiva®).
Box 5: HIV Drugs
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3. The third class of antiviral drug works at the time when the new
virus within the body matures and blocks the raw material for new
HIV virus from being cut by the protease enzyme that enables it
to be assembled into a functioning virus. Ten protease inhibitors
have been approved.
4. The newest class of ARV drug includes fusion inhibitors. They
prevent HIV from attaching to a cell during one of the first stages
of the HIV life cycle. Only one fusion inhibitor has been approved:
Enfuvirtide (T-20, Fuzeon®)
Source: Adapted from www.aids.org/Factsheets/403-What-is-Antiviral-Therapy.html
3.2.3 Microbicides
In the absence of a vaccine, novel biomedical methods for the prevention of HIV transmission
such as microbicides are being seen as an important potential weapon against HIV infection.
“Microbicides have the potential to give many women in developing countries the power,
for the first time, to control their risk of contracting HIV and other sexually transmitted
diseases” said Hilary Benn, the UK's international development secretary. Jonathan Weber,
professor in genito-urinary medicine and communicable diseases at Imperial College London,
backed that view: “We desperately need new methods to prevent HIV transmission in the
face of rising prevalence of infection globally. “As we have still not been able to develop
an effective HIV vaccine, vaginal microbicides are now the most promising bio-medical
intervention for the prevention of HIV infection on the horizon.” (BBC news Tuesday, 23
March 2004).
Microbicides are chemical agents with the potential to be used topically by women within
the vagina to prevent HIV and other sexual transmitted diseases. Candidate agents that
block the HIV virus binding to cells currently being investigates include several high molecular
weight anionically charged sulphated polymers such as PRO 2000 (a naphthalene sulphonate
polymer). PRO 2000 has been extensively studied in vivo and is now in phase III trials
in women at risk of HIV infection in Africa. In addition, research attention is being directed
at the possibility of using oral antiretroviral therapy, specifically tenofovir, for pre-exposure
prophylaxis (PrEP) to prevent HIV infection (Weber et al. 2005). As of June 2008, there
were 11 candidates in clinical development, three of which were being evaluated in ongoing
phase II/IIB or phase III trials (see Table 4).
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Table 4: On-going Microbicide Clinical Trial Projects
Phase
3
2B
2/2B
1
N/A
Candidate
PRO 2000/5 gel
Tenofovir gel
PRO 2000/5 gel (P)
and BufferGel®
Dapivirine (TMC120) gel
Ethanol in
Emollient Gel
HEC/CS/N-9†
Tenofovir/PMPA gel
Tenofovir gel
UC-781 gel
UC-781 gel
UC-781 gel
UC-781
UC-781
VivaGel™
(SPL7013 gel)‡
Placebo ring±
Partners
Indevus, MRC, DFID
(Funder)
CAPRISA, USAID, LIFElab,
Gilead, FHI, CONRAD
NIAID, Indevus, ReProtect
IPM
NIAID
CONRAD/USAID
CONRAD, IPM/USAID
NIAID
NIAID, CONRAD
UCLA, NIAID, CONRAD
CDC, Thailand Ministry of
Health, CONRAD
CONRAD
CONRAD, CDC, Emory
University
DAIDS/NIAID, NICHD,
Starpharma
IPM
Countries
South Africa, Tanzania,
Uganda, Zambia
South Africa
Malawi, South Africa,
United States, Zambia,
Zimbabwe
Belgium
Kenya
USA
Dominican Republic,
United States
United States
United States
United States
Thailand
United States
United States
Puerto Rico, United States
Kenya, South Africa,
Tanzania
Source: http://www.global-campaign.org/candidates.htm. Accessed 15 August 2008
Global Partnerships and networks of collaborators enabled such a rapid development of
the field. The Alliance for Microbicide Development, an alliance of scientists, product
developers and advocates, began in 1998 to coordinate and promote investment in, and
development of, microbicides. Four years later saw the formation of a public-private partnership,
the International Partnership for Microbicides (IPM), to assist with financial and regulatory
issues.
Partnering with academia and industry is helping to move science along much more rapidly
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than any single group could accomplish alone. Advocacy has increased and financial support,
prompted by the Bill and Melinda Gates Foundation, has increased from national governments,
WHO, European Union for finding a vaccine. A structured technology platform like MMV
or IPM that combines different disciplines and expertise to facilitate understanding the
biology of difficult diseases, has accelerated the discovery of promising new mechanisms
and compounds.
3.3 ‘Social’ Technology Innovations
Ensuring successful innovation of generic and disease specific technologies as outlined
in Section 1 is not straightforward. The organisational and institutional mix within which
technologies are produced and distributed also requires attention. Our mapping exercise
and review of the literature highlighted the importance of what we term ‘social technologies’.
It argued for the importance of a systemic approach to technological innovation. It is important
to consider integrated approaches that take into account the whole innovation cycle and
not only discrete aspects of it at any one time. The first step towards this, and as pointed
out by many of the survey respondents is, the need for better health systems.
3.3.1 Health Systems
David Weatherall and his colleagues in the DCP2 report write “As well as the mainstream
biomedical sciences, research into providing health care for the future will require a major
input from the social and behavioural sciences and health economics.” Although not a
technological advance as per the biomedical advances discussed above, the importance
of functioning health systems can be seen as a ‘social technology’ that has the potential
to address Africa’s health challenges in a way biomedical technological advances cannot.
This is because, as one respondent to our survey put it, “the strengthened health system
is the “magic gun” for all the “magic bullets” that will be developed.” A strong health system
(the institutions and mechanisms within which healthcare is produced, financed, governed
and provided) is required for all the biomedical technological advances to succeed.
Many developing countries, particularly in Africa, suffer from health systems that lack
resources (funding, infrastructure, personnel) and knowledge (skilled personnel). This has
implications on how medical research is conducted, what health technologies are produced
as well as when and in what manner these technologies are made available and accessible
to those that need them. Take the example of HAART used at the beginning of this study.
HIV/AIDS as a disease is evolving all the time, constant research is required to ensure
that drugs that are available to treat the disease are effective. Research that considers
the effectiveness and efficacy of AIDS drugs is being carried out in research institutes in
a number of African countries but a few such as the Kenya Medical Research Institute
(KEMRI) have sufficient trained staff and access to technology to measure CD4 counts,
viral loads and drug resistance. And even here there are issues around ensuring a pool
of well-trained researchers are available from the countries educational establishments.
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KEMRI benefits from international partnerships with groups such as the Wellcome Trust
and Swiss Tropical Institute which assists in capacity building activities but not all countries
have these links. And although the research is being conducted not everyone in Kenya
has access to AIDS drugs when they need them. This is due to issues on the demand and
supply side. At times there is not the supply of drugs that are required and where supplies
are available they are not able to guarantee the same drug regimen is available. This makes
it difficult to ensure compliance with drug taking as it becomes confusing for AIDS sufferers
as to which drugs to take, when. More specifically, however, on the demand side are issues
of cost. Very rarely are anti-retroviral drugs given for free and when they are the cost of
purchasing the drugs to the provider can mean that only the cheaper older lines of the
drugs are affordable.
Strengthening health systems requires an in-depth analysis of all aspects of their performance
(financing, production, governance and provision). In order to ‘fix’ health systems it has
been suggested that an integrated and systemic approach is required:
“institutions and agencies concerned with improving the currently grim health
outlook in Africa must take a more systemic approach -- turning at least some
of their attention to apparently mundane matters within the health system, such
as infrastructure, training, capacity building, human resources, and health
planning, that form the foundation for future advances in the well-being of
Africa's citizens.” (De Savigny et al. 2004)
A well known example is the work of TEHIP in Tanzania which worked to strengthen district
health care planning activities through linking data collection techniques regarding burden
of disease with budget calculations along with capacity building of staff in the techniques.
This project took an integrated approach to strengthening the health system in order to
address the district’s health challenges.
Another example of strengthening the health system through integrated approaches is
provided by Ethiopian malaria control activities. Supported by several development organisations,
the Ethiopian government is undertaking an integrated malaria control approach. The
emphasis is not simply on provision of anti-malarial drugs to treat malaria but on prevention
through the distribution of insecticide treated mosquito bednets and its working to strengthen
treatment activities through the use of rapid diagnostic test kit provision for health posts
as well as recommending and improving access to an artemisinin based drug for which
the malaria parasite has not developed resistance yet.
Strengthening and building effective health systems is only one part of the answer. It is
important – as stressed in Section 1 – to build up the whole process to ensure technologies
move from bench to bedside. This requires a holistic approach taking the idea of an innovation
cycle as the starting point for more problem-orientated innovation that stresses the linkages
and disconnects between the different actors and institutions involved in the whole innovation
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process. Most important for health innovation is to strengthen the links – to work out how
to build better links via innovation practices – that is, to work out how integrated approaches
can solve health problems. Strengthening one element in isolation from the others is a
means to an end, but not the end itself.
In stressing the importance of social technologies it is not possible to put together a list
of what is required; there is a lack of evidence as to ‘what works’ unlike for many of the
diseases currently affecting the poorest populations in Africa while ‘what works’ in one
place may not meet the requirements in another. Attempts have been made to outline what
is required to ensure a functioning health system (WHO 2001; Jamison et al. 2006b) in
terms of the determinants or ‘pillars’ that make up the ‘system’: information and infrastructural
inputs, management, human resources and financing. Thus some countries may require
an emphasis being placed on data collection in order to match health system and health
research responses to disease burden or a better medicines supply chain. Other countries
may require stronger leadership and policy support or ways to retain and train medical
staff. Then there are countries that need to balance the needs and financing of public sector
health care provision with the often used but unregulated private sector suppliers. Many
countries require a combination of these activities. This also requires – particularly when
a holistic innovation systems lens is used – interaction with those placed outside of the
realm of ‘health’ or even ‘research’ and ‘science and technology’. A functioning health
system requires interactions with systems of education, finance, regulation and law, politics
etc.
3.4  Potential and Impact of New Technologies on Health Systems
In the previous section we listed three broad types of technological advance with potential
to address Africa’s health challenges. These all have the chance to reduce the burden
created from diseases such as HIV/AIDS, TB, malaria and cholera etc. To be successful
in the introduction, adoption and development of any of these technologies it is however
necessary to consider various technological constraints affecting their implementation and
development. At the same time, and as highlighted by the implications of ‘social technologies’,
there is a need to consider the importance of building robust health innovation systems
that provide a way to create enabling environments that will empower the integration of
new science and technology with the potential to address Africa’s health challenges.
The successful introduction and uptake of technologies relies on a complex relationship
with social, economic and political forces. There are numerous examples of technologies
that have not successfully been introduced or produced due to inabilities to understand
or contend with forces external to the technology itself. AIDS vaccine research has been
constrained by scientific uncertainty while the female condom has been plagued by a
combination of its design and subsequent attitudes towards it. Even where a product is
available and efficacious, for example in the case of polio vaccination efforts, traditional
beliefs and attitudes amongst communities, reiterated at times by community leaders, has
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also hampered progress. Thus, it is important to consider both:
1. Constraints affecting each technology in its advance;
2. The wider enabling environment constraints.
These will now be discussed in turn.
3.4.1 Constraints Affecting a Technology’s Progress
Sequencing of genomes as a technology has great potential in providing the first step
towards addressing the health challenges faced by Africa. As highlighted above, the
opportunities afforded by being able to isolate and understand individual genes has provided
the catalyst for breakthroughs in diagnostic PCR technology as well as malaria drug
development. Unfortunately issues exist regarding the capacity of African science bases
to become involved in this technology. However a number of African countries are using
and developing the technologies, such as PCR, that result as a consequence of information
gained from sequencing genomes. As was highlighted above, the Top 10 report placed
diagnostic tools as having the greatest potential to address health challenges. This is
because many diagnostic tools currently exist and are in use throughout the world. PCR
technologies and new developments in diagnostic testing are transforming the speed at
which disease diagnosis and detection occur. However the cost of these technologies
sometimes makes them less available to developing countries. A variety of new recombinant
drugs and vaccines are available and some cost less to produce than older varieties,
however, recombinant vaccines are still not available for HIV, malaria and TB (although
progress is being made) and issues of resistance hamper some development efforts. One
of the biggest issues affecting drug and vaccine development however is their delivery
systems. This issue is linked to the need for stronger health systems, the ‘social technology’
listed above. Allied to the need for stronger health systems is an increasing awareness
of the social determinants of health5 of which hunger and poverty is one. The potential
offered by GM crops as a means of increasing (more nutritious) food production is seen
as a means of working to reduce hunger and poverty in developing countries.
Thus each of these different technological advances are at different stages of existence
and have differing potential impact in terms of reducing burden of disease. This is not only
in terms of their impact in controlling disease through providing treatments but also in terms
of prevention activities. The TEHIP example given above provides a case where decisions
regarding what areas of disease control should be focused on where weighed against
budgetary constraints and current burden of disease within the local health districts. These
kinds of priority setting issues are important when considering which of the above technologies
has the potential greatest impact on Africa’s health challenges but made more difficult by
the lack of predictability in science (see below). The Council on Health Research for
Development (COHRED) has worked extensively with the Alliance for Health Policy and
Systems Research to consider successful priority setting of health research agendas following
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the work of the Ad hoc Committee on Health Research6. If choices have to be made as
to which of these technologies a country should focus its attention undertaking priority
setting activities are the first step to take as exemplified by the South African government
who set up a foresight process following the identification of research priorities using the
Essential National Health Research approach.
3.4.2 Enabling Environment Constraints
The potential these technologies have to address Africa’s health challenges is dependent
on a number of constraints that they face at the various stages of their development. A
number of these have already been made mention to above and have also been covered
in Chataway et al. (2007). These and other constraints that affect the impact these technologies
will have on addressing Africa’s health challenges will now be discussed in a little more
depth.
The Unpredictability of Science
A very important constraint can be the strict process of priority setting. This can limit the
areas where major advances are discovered. Science is not always predicable but can
occur very much the result of chance. This was the case for Jenner in discovering that
smallpox could be vaccinated against using cowpox and how, more recently, penicillin was
discovered. Science requires a degree of freedom to explore but also a degree of connectivity
as science also requires interaction and dialogue between scientists and researchers. A
further science related constraint is the more practical constraint faced by rising drug
resistance by pathogens. There is a need for flexible policies to work with these to ensure
for example that new drugs and vaccines can be introduced as and when required before
resistance comes to dominate. Secondly, science is not always the responsibility of, or
possible at, national level. Leading edge science (like a new vaccine for HIV/AIDS) relates
at times to a global risk, not a national one. However, getting local capacity to test for
vaccines and drugs is a national level activity. There needs to be the flexibility, integration
and understanding to provide for this.
Skills Availability
The continent suffers from an overarching constraint in respect of the skills sets available
in the areas of health and science and technology. In R&D activities there is a lack of
trained staff to work in laboratories and little opportunity for such experience in the educational
setting. In the healthcare setting there is an increasing lack of staff who are willing to work
when more money can be made working in other occupations or other countries. This
reduces the capacity, particularly in the public sector, for healthcare providers to distribute
and use these technologies. There are also gaps in capacity at the policy level which
impacts the quality of the decision making and governance process within which these
technologies are advanced. The heavy burden HIV/AIDS is having on the continent is also
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playing a part in affecting the numbers of the health and science and technology workforce.
The issue of skills is not simply one of individual level human capital, in many instances
there is a need to build team-orientated and project management approaches; there are
times when groups of experts with various specialisms are required to ensure problems
are overcome in a clinical, R&D, project management and policy level.
Make or Buy Decisions
In the case of diagnostics and some vaccines and drugs the technologies are available
and decisions have to be made about whether it makes sense to buy technologies or
develop domestic manufacturing capabilities. South Africa, Kenya, Nigeria and Egypt have
built strong diagnostic, drug and vaccine manufacturing capabilities at present. However,
ensuring manufacturing capability requires serious financial investment and the prospects
of markets. There are also issues regarding economies of scale of production that make
it difficult to ensure the sustainability of manufacturing capability for some drugs in Africa.
This is one reason the World Bank has argued that production will remain in the hands
of a small number of large manufacturers and as such most countries should buy in
pharmaceutical products such as ARVs produced from elsewhere (Rovira 2004). However,
a number of firms are starting to produce generic ARVs particularly through joint ventures.
One example is Quality Chemicals in Uganda produce ARVs in a joint venture with Cipla
Pharmaceuticals of India from June 2007 (Anderson 2006).
The same decisions come into play when decisions are made regarding the development
of a country’s own basic research and development facilities. In trying to encourage the
development of R&D South Africa has set up innovation hubs, centres around which
incentives and subsidies are given to companies wishing to invest to start up an R&D
company, particularly in the area of biotechnology. In other places public-private partnerships
are emerging that are providing a means to build scientific capacity on the ground (Chataway
and Smith 2006) suggesting solutions can be found to this constraint around a decision
to get involved in production of R&D.
Purchasing Power
Constraints relating to purchasing power can be found in both the supply and demand.
On the supply side there are constraints in terms of ensuring that the infrastructure and
equipment are able to be purchased to do good quality basic research and to have first
class manufacturing capability. Recently Zambia announced that it was unable to afford
new diagnostic tools and was having to rely on older methods to conduct medical tests
(Ngandwe and Tallaksen 2006). As has been highlighted above public private partnerships
have been suggested as a means of moving forward in this area. However the impact of
the private sector on health care has been, and continues to be hotly debated (Soderlund
2003). Similarly there are constraints created from purchasing power issues on the demand
side. In many countries there is a lack of purchasing power within the general public who
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have to access healthcare services. These exacerbate issues of equity of, and access to,
healthcare.
Regulation and Quality Control
Whether a decision is made to conduct basic research or manufacture in-country or import
ready produced technologies from outside, products are required to be of high quality and
well regulated. Unfortunately, regulatory and quality assurance networks tend to be weak
in many countries and regionally. The situation is improving in areas such as clinical trials
of new drugs and vaccines where a demand is being placed on all those involved having
been trained in Good Laboratory Practice or Good Clinical Practice and some laboratories
have been given international accreditation to conduct clinical trial work e.g. the Kenyan
AIDS Vaccine Initiative in Kenya. However, the quality of many manufactured drugs both
those imported and manufactured locally can be poor. The efforts of Dora Akunyili, Nigeria’s
Head of the National Food and Drug Administration and Control, show that improvements
can be made but it has been argued that there is a need for more emphasis on cooperation
and training to build regional regulation and to use WHO’s pre-qualification process to
ensure quality, safety and efficacy of medicines (Gray 2004).
Policy Environment
Having policy makers who understand the value of a functioning health system goes a
long way towards ensuring that goal. Similarly, it is important that policy makers understand
and value the potential of these technologies in order for them to push the requirements
needed to ensure these technologies are produced and delivered. Secondly, there is a
need for them to work together to realise that it is not just an issue of science or of healthcare
delivery but of gaps within a wider system of health innovation (see Chataway et al. 2007).
Access Issues
One aspect of the access issue relating to the last element of the innovation cycle is how
to ensure compliance with treatment doses and regimens by both medical staff and patients
themselves. One mechanism to overcome this has been the development of pre-packaged
drugs to aid correct treatment action. This relates to a wider issue of general awareness
and understanding regarding technology. A number of studies have found that communities
and policy makers alike may not understand the mechanisms of technological advance,
say for example the process of clinical trials (cf. Leach and Fairhead 2005). There can
also be little understanding regarding the need for, or value of, new technologies. Gaining
understanding is not the only issue that hinders good delivery. Ensuring any of the technologies
listed above are delivered requires a combination of constant and reliable delivery mechanisms,
safe and regulated supplies as well as trained staff to deliver and use the technologies.
These require a functioning and effective health system i.e. a system that is able to effectively
finance, produce, govern and deliver healthcare and its related activities. This also makes
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clear that access issues are multiple and are not just limited to the last stage of the innovation
cycle. Access is required to all information, skills and personnel throughout the innovation
cycle. Without these it will not be possible to build functioning and effective health innovation
systems.
Thus although these technologies have much potential to address Africa’s health challenges
and many are available for use and delivery having been successfully developed there are
a number of constraints that hold up their ability to address these health challenges. The
next section will consider these issues and come up with a number of policy recommendations.
4. Conclusion and Policy Recommendations
A very significant momentum has built up in relation to the problem of neglected diseases
in Africa and particularly in using scientific and technological tools to further capacity to
treat disease and ill health. In the last decade there has been an explosion of new initiatives
in this area. The challenge now is to make sure that this momentum is continued and leads
to the construction of the kind of capacities that will enable Africans to benefit from good
health on a more sustained basis.
Below we have put together some of the main policy recommendations of ways African
countries can move forward. There is no universal ‘one size fits all’ formula. Nothing that
has been outlined in this study may be suitable to be taken up by all countries in Africa.
Successful development of health related technologies or technology based health products
requires productive organisations and institutions, it requires the right ‘social technology’.
It requires a consideration of all issues and activities that relate to innovative technology
in a systemic way. It is necessary to consider not only the constraints affecting a particular
technology’s progress but also the wider enabling environment constraints listed in Section
3.4.
There is no one framework or model of activities that each country can undertake nor is
there a single checklist of areas that each must consider. Each country, each initiative and
each new technology has, and will, evolve in individual and quite separate ways with different
types and strengths of linkages and interactions being made that both stimulate and detract
from innovation.
One set of key and current policy issues for African countries is where future improvements
might be made quickest and to best advantage. Deciding which scientific and technological
advances to choose and how best to provide the ‘social technology’ to aid their development
requires strong strategic planning and priority setting activities.
Undertake strategic planning and priority setting that starts with foresight activities to identify
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the best mix of scientific and social technologies.
In thinking about health innovation systems a move is made from thinking in terms of
discrete areas of activity and towards the wider architecture of actors and linkages required
to ensure a technology is developed and/or introduced. This creates a means of ensuring
not only that technology is developed or delivered but that it is also taken up and used
– something that currently is not often considered. Currently, an emphasis is often placed
on getting treatments out using top-down approaches that tend to ignore the complexity
on the ground when attempting to introduce a technology.
Create Health Innovation and Development Platforms
Health Innovation and Development Platforms would most likely be problem-oriented platforms
rather than science-led or health system pulled. They would build on, but also go way
beyond the idea of cross-functional teams in product development. In the same way that
the new global initiatives for technologies – e.g. for vaccines or new drug regimes for TB,
have emerged, these new platforms would be ambitious and would need to include science,
technology and innovation capabilities as well as health systems capabilities. They would
be dedicated to improving coordination and understanding of different product development
and treatment efforts and would be a way for the African Union and NEPAD to play a direct
role in policy making in the development of health innovation and coordinated capacity
building in health systems. These platforms will need to be very ambitious but are very
necessary if the ‘problem-orientation’ is not to stop with new innovative products that cannot
be delivered. Designing new health delivery systems would then be a part of the innovation
process reducing the disconnect between innovation of technology and development of
healthy populations.
Platforms should allow for regional and international level activities
In order to access all the resources and capabilities a platform might require there would
need to be mechanisms through which linkages could be made to regional and international
actors. In many instances there are likely to be large overlaps and similarities between
different country’s platform mechanisms and objectives. There would need to be explicit
approaches to build more universal principles and to learn from one location to another
so as not to have to ‘reinvent the wheel’. One way of achieving this would be to regionally
organise the platforms to make the most of regionally available expertise. The NEPAD and
African Union frameworks provide one mechanism through which to organise such platforms.
Similarly the ability to make linkages with international organisations and countries outside
of the region will need to be encouraged.
Notes
1. These are defined as those diseases that predominately affect the poorest populations who lack the purchasing
power to buy the medicines needed. The diseases also receive less attention from international pharmaceutical
companies and donor funding. There are increasing calls that this definition be used in a narrower sense to refer
only to a list of diseases (excluding the ‘big three’ of HIV/AIDS, malaria and tuberculosis) such as schistosomiasis,
lymphatic filariasis, onchocerciasis, and trachoma (Hotez et al. 2005).
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AU/NEPAD 2005. Africa’s Science and Technology Consolidated Plan of Action, August 2005.
AU/NEPAD 2006. Freedom to innovate: Biotechnology in Africa’s Development. Draft Report of the
High-Level African Panel on Modern Biotechnology of the African Union (AU) and
the New Partnership for Africa’s Development (NEPAD), July 14, 2006, available
at www.nepadst.org/doclibrary/pdfs/abp_july2006.pdf.
Anderson, T. 2006. Africa Rises to the HIV drug challenge.
http://news.bbc.co.uk/1/hi/business/5027532.stm.
Badri, M., L.G. Bekker, C. Orrel, J. Pitt, F. Cilliers and R. Wood 2004. Initiating highly active anti-
retroviral therapy in Sub-Saharan Africa: an assessment of the revised WHO scaling-
up guidelines. AIDS 18(8).
Bentley, D.R. 2004. Genomics for Medicine. Nature May 2004.
CASP 2006. Report of the 1st African Congress of Scientists and Policymakers, 1st Ordinary Session,
Alexandra, Egypt, 27-29 October 2006, www.icsu-africa.org/casp_rep.pdf.
Chataway, J., J. Smith and D. Wield 2007. Shaping scientific excellence in agricultural research.
International Journal of Biotechnology Forthcoming.
Chataway, J. and J. Smith 2006. The International Aids Vaccine Initiative (IAVI): Is it getting new
science and technology to the world's neglected majority? World Development,
34(1).
Cohen, J. 2008. Treatment and prevention exchange vows at international conference. Science 321
(5891): 902-903.
Commission for Africa 2005. Our Common Interest: Report of the Commission for Africa
www.commissionforafrica.org.
Crump, J.A., P.O. Otieno, L. Slutsker, B.H. Keswick, D.H. Rosen, R.M. Hoekstra, J.M. Vulule and S.P.
Luby 2005.Household based treatment of drinking water with flocculant-disinfectant
for preventing diarrhoea in areas with turbid source water in rural western Kenya:
cluster randomised controlled trial” BMJ 26 July 2005.
Daar, A.S., H. Thorsteinsdóttir, D.K. Martin, A.C. Smith, S. Nast and P.A. Singer 2002. Top ten
biotechnologies for improving health in developing countries. Nature Genetics 32(2):
229-232.
Department of Arts, Culture, Science and Technology 1996. White Paper on Science and Technology
www.dst.gov.za/publications/white_papers/Science_Technology_White_Paper.pdf.
2. The definition of ‘biotechnology’ used throughout the reports and our survey relates to a wide definition of biotechnology
as any technological application of biological or living organisms.
3. This is usually defined to refer to technologies that facilitate, or are facilitated by, communication and social processes.
Our use of this term differs slightly in that we denote an organisational and institutional mix that is one part of the
process of ensuring successful innovation.
4. Recombinant DNA (rDNA) technology is a field of molecular biology. The practice of cutting, pasting, and copying
DNA dates back to Arthur Kornberg's successful replication of viral DNA in a breakthrough that served as a proof-
of-concept for cloning. This was followed by the Swiss biochemist Werner Arber's discovery of restriction enzymes
in bacteria that degrade foreign viral DNA molecules while sparing their own DNA. Arber effectively showed geneticists
how to "cut" DNA molecules. This was followed by the understanding that ligase could be used to "glue" them
together. These two achievements launched rDNA technology research.
5. As evidenced by the setting up of the WHO Commission on Social Determinants of Health.
6. See www.cohred.org and www.alliance-hspr.org & the work of WHO’s Ad hoc committee on health research
concerning future intervention options e.g. 1996 report, “Investing in health research and development” Geneva:
WHO.
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